Cambridge Investment Research Advisors Inc. Makes New $180,000 Investment in INmune Bio, Inc. (NASDAQ:INMB)

Cambridge Investment Research Advisors Inc. purchased a new position in shares of INmune Bio, Inc. (NASDAQ:INMB) in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The firm purchased 23,075 shares of the company’s stock, valued at approximately $180,000. Cambridge Investment Research Advisors Inc. owned about 0.10% of INmune Bio as of its most recent filing with the SEC.

Several other hedge funds have also recently added to or reduced their stakes in the company. Fermata Advisors LLC raised its holdings in INmune Bio by 6.4% during the 1st quarter. Fermata Advisors LLC now owns 49,997 shares of the company’s stock worth $390,000 after purchasing an additional 3,000 shares during the last quarter. Rhumbline Advisers raised its holdings in INmune Bio by 14.4% during the 1st quarter. Rhumbline Advisers now owns 19,153 shares of the company’s stock worth $150,000 after purchasing an additional 2,409 shares during the last quarter. Two Sigma Advisers LP bought a new position in INmune Bio during the 4th quarter worth approximately $59,000. Two Sigma Investments LP raised its holdings in INmune Bio by 444.8% during the 4th quarter. Two Sigma Investments LP now owns 66,384 shares of the company’s stock worth $310,000 after purchasing an additional 54,200 shares during the last quarter. Finally, Millennium Management LLC raised its holdings in INmune Bio by 43.9% during the 4th quarter. Millennium Management LLC now owns 291,327 shares of the company’s stock worth $1,360,000 after purchasing an additional 88,823 shares during the last quarter. Institutional investors own 12.72% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have issued reports on INMB shares. Maxim Group lowered their price target on shares of INmune Bio from $30.00 to $8.00 and set a “buy” rating for the company in a report on Wednesday, July 2nd. Raymond James Financial lowered shares of INmune Bio from a “moderate buy” rating to a “hold” rating in a research note on Monday, June 30th. BTIG Research reiterated a “neutral” rating on shares of INmune Bio in a research note on Tuesday, July 1st. Finally, Scotiabank reiterated a “sector underperform” rating on shares of INmune Bio in a research note on Tuesday, July 1st. One research analyst has rated the stock with a sell rating, two have issued a hold rating, three have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, INmune Bio presently has a consensus rating of “Moderate Buy” and a consensus price target of $18.40.

INmune Bio Stock Down 8.2%

NASDAQ:INMB opened at $2.12 on Tuesday. The company has a fifty day moving average of $6.33 and a 200-day moving average of $7.19. The firm has a market capitalization of $49.99 million, a P/E ratio of -1.10 and a beta of 1.34. INmune Bio, Inc. has a twelve month low of $1.89 and a twelve month high of $11.64.

INmune Bio (NASDAQ:INMB) last announced its quarterly earnings results on Thursday, May 8th. The company reported ($0.43) EPS for the quarter, meeting analysts’ consensus estimates of ($0.43). The business had revenue of $0.05 million for the quarter. On average, analysts anticipate that INmune Bio, Inc. will post -2.24 EPS for the current fiscal year.

About INmune Bio

INmune Bio, Inc, a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation.